trending Market Intelligence /marketintelligence/en/news-insights/trending/di4pxy6uv-wodk-3tk-7fq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Regulus Therapeutics director to retire

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Regulus Therapeutics director to retire

Regulus Therapeutics Inc. said director Mark Foletta will retire from the board upon the expiration of his current term ending at the 2018 annual meeting of stockholders.

The San Diego, Calif.-based company said Foletta's decision was a result of his concurrent service as the executive vice president and CFO for cancer drug developer Tocagen Inc.